Kamada (NASDAQ:KMDA) Upgraded at Wall Street Zen

Wall Street Zen upgraded shares of Kamada (NASDAQ:KMDA) from a hold rating to a strong-buy rating in a research note released on Saturday.

Other research analysts also recently issued research reports about the stock. William Blair set a $15.00 price target on shares of Kamada in a report on Tuesday, July 21st. Weiss Ratings cut Kamada from a “buy (b)” rating to a “buy (b-)” rating in a research note on Thursday, June 25th. Finally, Benchmark restated a “buy” rating on shares of Kamada in a research report on Tuesday, July 21st. Three equities research analysts have rated the stock with a Buy rating, Based on data from MarketBeat, the company presently has an average rating of “Buy” and an average target price of $13.00.

Kamada Stock Up 2.4%

Kamada stock opened at $7.76 on Friday. Kamada has a 52-week low of $6.50 and a 52-week high of $9.35. The firm’s fifty day moving average is $7.23 and its 200 day moving average is $7.95. The company has a market cap of $446.28 million, a price-to-earnings ratio of 20.42, a PEG ratio of 0.67 and a beta of 0.86.

Kamada (NASDAQ:KMDA) last issued its quarterly earnings data on Wednesday, August 12th. The biotechnology company reported $0.16 EPS for the quarter, topping analysts’ consensus estimates of $0.11 by $0.05. Kamada had a net margin of 11.60% and a return on equity of 8.37%. The business had revenue of $54.92 million during the quarter, compared to analysts’ expectations of $50.84 million. On average, equities research analysts anticipate that Kamada will post 0.45 earnings per share for the current fiscal year.

Kamada Cuts Dividend

The company also recently declared an annual dividend, which will be paid on Thursday, September 17th. Investors of record on Thursday, August 27th will be paid a dividend of $0.17 per share. The ex-dividend date of this dividend is Thursday, August 27th. This represents a dividend yield of 219.0%. Kamada’s payout ratio is currently 50.00%.

Hedge Funds Weigh In On Kamada

Several hedge funds have recently added to or reduced their stakes in the company. Barclays PLC raised its position in Kamada by 417.1% in the 4th quarter. Barclays PLC now owns 4,788 shares of the biotechnology company’s stock worth $34,000 after purchasing an additional 3,862 shares during the period. China Universal Asset Management Co. Ltd. purchased a new position in shares of Kamada during the fourth quarter valued at approximately $66,000. XTX Topco Ltd purchased a new position in shares of Kamada during the fourth quarter valued at approximately $103,000. SIH Partners LLLP bought a new position in shares of Kamada during the fourth quarter valued at approximately $134,000. Finally, Quadrature Capital Ltd grew its stake in shares of Kamada by 53.5% during the fourth quarter. Quadrature Capital Ltd now owns 21,889 shares of the biotechnology company’s stock valued at $155,000 after buying an additional 7,627 shares during the last quarter. 20.38% of the stock is currently owned by institutional investors.

Kamada Company Profile

Kamada Ltd. is a biopharmaceutical company headquartered in Israel that specializes in the development, manufacturing and commercialization of plasma?derived protein therapeutics. The company focuses on treatments for rare and serious diseases, leveraging its proprietary fractionation and purification technologies to produce purified human proteins. Kamada’s product portfolio addresses critical therapeutic areas in immunology, hematology and pulmonology, where alternative treatment options may be limited.

Among Kamada’s marketed products is Glassia®, an alpha?1 antitrypsin augmentation therapy approved by the U.S.